title: Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication.
abstract: Chronic prolonged excretion of vaccine-derived polioviruses by immunodeficient persons (iVDPV) presents a personal risk of poliomyelitis to the patient as well as a programmatic risk of delayed global eradication. Poliovirus antiviral drugs offer the only mitigation of these risks. Antiviral agents may also have a potential role in the management of accidental exposures and in certain outbreak scenarios. Efforts to discover and develop poliovirus antiviral agents have been ongoing in earnest since the formation in 2007 of the Poliovirus Antivirals Initiative. The most advanced antiviral, pocapavir (V-073), is a capsid inhibitor that has recently demonstrated activity in an oral poliovirus vaccine human challenge model. Additional antiviral candidates with differing mechanisms of action continue to be profiled and evaluated preclinically with the goal of having 2 antivirals available for use in combination to treat iVDPV excreters.
authors.affiliation: Center for Vaccine Equity, The Task Force for Global Health, Decatur, Georgia ViroDefense Inc., Rockville, Maryland Centers for Disease Control and Prevention, Atlanta, Georgia World Health Organization, Geneva, Switzerland Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire Center for Vaccine Equity, Task Force for Global Health, Decatur, Georgia.
authors.forename: Mark A
authors.initials: MA
authors.lastname: McKinlay
authors.affiliation: ViroDefense Inc., Rockville, Maryland.
authors.forename: Marc S
authors.initials: MS
authors.lastname: Collett
authors.affiliation: ViroDefense Inc., Rockville, Maryland.
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Hincks
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia.
authors.forename: M Steven
authors.initials: MS
authors.lastname: Oberste
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Pallansch
authors.affiliation: World Health Organization, Geneva, Switzerland.
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Okayasu
authors.affiliation: World Health Organization, Geneva, Switzerland.
authors.forename: Roland W
authors.initials: RW
authors.lastname: Sutter
authors.affiliation: Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
authors.forename: John F
authors.initials: JF
authors.lastname: Modlin
authors.affiliation: Center for Vaccine Equity, Task Force for Global Health, Decatur, Georgia.
authors.forename: Walter R
authors.initials: WR
authors.lastname: Dowdle
mesh_terms: D000998:Antiviral Agents / Q000302:isolation & purification* / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D060740:Disease Eradication / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D016867:Immunocompromised Host; D011051:Poliomyelitis / Q000517:prevention & control*; D017955:Poliovirus / Q000187:drug effects*; D012308:Risk Management; D017201:Virus Shedding
chemical_list: D000998:Antiviral Agents
keywords: antiviral; poliovirus